PAVmed is a diversified life sciences company that operates through independently financed subsidiaries focused on medical devices, diagnostics, and digital health. Its core business includes Lucid Diagnostics, which develops cancer prevention diagnostics for esophageal precancer detection through the EsoGuard DNA methylation assay and EsoCheck noninvasive cell collection device, targeting millions of at-risk gastroesophageal reflux disease patients; Veris Health, a digital health platform that monitors cancer patients during treatment and survivorship through remote physiological data collection and telehealth integration; and a pipeline of implantable medical devices including the PortIO intraosseous vascular access system and licensed endoscopic imaging technology. The company generates revenue through multiple channels: diagnostic testing reimbursement from insurance and direct contracts, software-as-a-service subscriptions from healthcare systems for digital monitoring platforms, and anticipated revenues from medical device commercialization.